A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts... It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie.
- Mechanism
- Curator reviewed
Bepridil has inhibitory effects on both the slow calcium (L-type) and fast sodium inward currents in myocardial and vascular smooth muscle, interferes with calcium binding to calmodulin, and blocks both voltage and receptor operated calcium channels. Bepridil inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle. This has been demonstrated in isolated myocardial and vascular smooth muscle preparations in which both the slope of the calcium dose response curve and the maximum calcium-induced inotropic response were significantly reduced by bepridil. In cardiac myocytes in vitro, bepridil was shown to be tightly bound to actin. Bepridil regularly reduces heart rate and arterial pressure at rest and at a given level of exercise by dilating peripheral arterioles and reducing total peripheral resistance (afterload) against which the heart works.
- Primary indication
- For the treatment of hypertension, and chronic stable angina (classic effort-associated angina).Curator reviewed
- Formula / weight
- C24H34N2O · 366.5396 g/mol (avg)
- Also known as
- 1-(2-(N-BENZYLANILINO)-1-(ISOBUTOXYMETHYL)ETHYL)-PYRROLIDINE · 1-PYRROLIDENEETHANAMINE, .BETA.-((2-METHYLPROPOXY)METHYL)-N-PHENYL-N-(PHENYLMETHYL)- · Bepadin
- Code names
- Org 5730
Resolves to
UIEATEWHFDRYRU-UHFFFAOYSA-NSMILESCC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1What you can answer from here — as of September 23, 2026
Which drugs share a target with Bepridil, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account